Liraglutide as anti-obesity agent
:Obese, non-diabetic people
:Phase 3
Obesity is an increasing global problem, which is associated with increased morbidity, including a significantly increased risk of developing type 2 diabetes. One of the main problems with existing obesity treatment is the sustainability of weight loss as many patients regain weight.
Liraglutide, Novo Nordisk’s once-daily, human GLP-1 analogue, has shown the potential in both preclinical studies as well as in non-diabetic human subjects to reduce food intake and induce weight loss.
- Company announcements
- Novo Nordisk provides update on corporate strategy at its Capital Markets Day (26 Sep 2008)
- Significant weight loss sustained in obese people treated with liraglutide for one year (16 Jun 2008)
- New phase 2 study shows that liraglutide leads to significant weight loss in obese people (20 Nov 2007)
- Read more company announcements
- Press releases
- No press releases matching the search criteria
- Scientific abstracts
- Diabetes (2007)
- Diabetes Obesity and Metabolism (2008)
- Diabetes Obesity and Metabolism (2008)
- Read more scientific abstracts
